Artificial intelligence in drug discovery: opportunities and limitations

The Beyond the Lab report highlights the increasing use of AI in drug discovery, including identifying targets, designing molecules, analyzing biological data, and supporting early-stage decision-making.
Despite rising investment, there are ongoing challenges in validation, reproducibility, and real-world application of AI technologies within drug discovery.
The report focuses on specific applications of AI in early drug discovery, such as designing and evaluating molecules, pursuing difficult targets using covalent chemistry, and building predictive virtual cell models.
Key experts from leading companies such as Inductive Bio, Expedition Medicines, and Insilico Medicine provide insights into the current state and future potential of AI in drug discovery.
Specific topics covered include the use of AI-powered virtual laboratories, the integration of AI workflows to accelerate timelines from target identification to candidate selection, and the importance of causality and mechanistic reasoning in pharmaceutical AI.
The report underscores the need for demonstrating value and overcoming limitations to encourage greater adoption of AI technologies in drug discovery.
To access detailed analysis and expert opinions, registration is required to view the full report.